- Home
- NEXN vs LYEL Comparison
NEXN vs LYEL Comparison
Compare NEXN & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEXN | LYEL |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | Israel | United States |
| Employees | 909 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.2M | 490.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NEXN | LYEL |
|---|---|---|
| Price | $6.60 | $20.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $11.69 | ★ $27.25 |
| AVG Volume (30 Days) | ★ 339.9K | 98.1K |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.60 | $0.39 |
| 52 Week High | $12.00 | $45.00 |
Technical Indicators
Market Signals| Indicator | NEXN | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | 38.72 |
| Support Level | $6.28 | $15.82 |
| Resistance Level | $6.85 | $27.30 |
| Average True Range (ATR) | 0.35 | 1.99 |
| MACD | -0.05 | -0.37 |
| Stochastic Oscillator | 28.29 | 17.72 |
Price Performance
Historical ComparisonAbout NEXN Nexxen International Ltd. American Depository Shares
Nexxen International Ltd is a globalized and flexible advertising technology platform with deep expertise in data and advanced TV that helps empower advertisers, agencies, digital publishers and broadcasters to achieve desired outcomes, including increased efficiency and returns, across the media supply chain. It is a demand-side platform (DSP), supply-side platform (SSP), ad server, and data management platform (DMP) and also delivers a flexible and unified technology stack with and exclusive data at its core. Company operates in America, APAC, EMEA, regions, with majority revenue from America.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.